Publications
Abstracts/Poster/Podiums
Over 50 presentations presented at a variety of scientific meetings over the last 20 years.
Publications by Papadopoulos G. accessible on Research Gate
Manuscripts
2015
Dranitsaris G, Papadopoulos G. Health Technology Assessment of Cancer Drugs in Canada, the United Kingdom and Australia: Should the United States Take Notice?
App. Health Econ Health Policy. 2015: 13(3); 291-302.
Click Here to Read
2013
Papadopoulos G, Hunt S, Prasad M. Adapting a Global Cost-Effectiveness Model to Local Country Requirements: Posaconazole Case Study.
J Med Econ. 2013: 16(3); 374-380.
Click Here to Read
2012
Ashley ED, Drew R, Johnson M, Danna R, Dabrowski D, Walker V, Prasad M, Alexander B, Papadopoulos G, Perfect J. Cost of Invasive Fungal Infections in the Era of New Diagnostics and Expanded Treatment Options.
Pharmacotherapy. 2012: 32(10); 890-901.
Click Here to Read
Tahami Monfared AA, O’Sullivan AK, Rotstein C,Papadopoulos G. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada.
Can J Infect Dis Med Microbiol 2012; 23(2):59–64.
Click Here to Read
O’Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston A, Perfect J, Papadopoulos G.
Cost-Effectiveness of Posaconazole Versus Fluconazole in the Prevention of Invasive Fungal Infections Among Patients with Graft-versus-Host Disease in the US.
Am J Health Syst Pharm 2012; 69:149-156
2011
Menzin J, Meyers J, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulos G.
The Economic Costs to United States Hospitals of Invasive Fungal Infections in Transplant Patients.
Am J Infect Control 2011; 39(4): 15-20
2010
Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A.
Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.
Oncology. 2010; 78(3-4): 172-80
Herbrecht R, Rajagopalan S, Danna R, Papadopoulos G.
Comparative Survival and Cost of Therapy: Posaconazole vs. Standard Antifungals in Treatment of Invasive, Refractory Aspergillosis.
Curr Med Res Opin 2010; Oct 26(10): 2457-64
2009
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G.
Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients.
Am J Health Syst Pharm. 2009 Oct 1;66(19):1711-7
O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC.
Cost-Effectiveness of Posaconazole versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States.
Value Health. 2009; 12(5): 666-673
2008
Brown JS, Neumann PJ, Papadopoulos G, Ruoff G, Diamond M, Menzin J.
Migraine Frequency and Health Utilities: Findings from a multi-site survey.
Value In Health 2008; 11(2):315-321
2007
Dahlöf C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L.
The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials.
Health Qual Life Outcomes 2007; 5: 56
2006
Brown JS, Papadopoulos G, Neumann PJ, Price M, Friedman M, Menzin J.
Cost effectiveness of migraine prevention: the case of topiramate in the United Kingdom.
Cephalalgia 26, 1473-82, 2006
Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S.
The impact of migraine on daily activities: effect of topiramate compared with placebo.
CMRO 2006; 22(6); 1021-1029,
Click Here to Read
2005
Diamond M, Dahlöf C, Papadopoulos G, Neto, Wu S-C,.
Topiramate improves health-related quality of life when used to prevent migraine.
Headache 2005; 45: 1023-1030
Brown J S, Papadopoulos G, Neumann P J, Friedman M,.Miller J D, Menzin J.
Cost effectiveness of topiramate in migraine prevention; results from a pharmacoeconomic model of topiramate treatment.
Headache 2005; 45: 1012-1022
2004
Fairclough D L, Gagnon D, Papadopoulos G. Planning Analyses of Quality of Life Studies: A case example withmigraine prophylaxis.
J Biopharm Stat. 2004; 13(41): 31-51
Stahl, SM, Markowitz, JS, Papadopoulos, G, Sadik, K.
Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease.
Current Medical Research and Opinion 2004; 20(4): 517-524
2003
Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O’Brien JA, Papadopoulos G for the AHEAD Study Group. Economic evaluation of galantamine for the treatment of mild to moderate Alzheimer’s disease in the United States
Current Therapeutics 2003; 25(6): 1806-25
Markowitz JS, Gutterman E, Papadopoulos G.
Health Related Quality of Life Among Caregivers with persons with Alzheimer’s Disease.
Alzheimers Disease and Associated Disorders 2003; 17: 209-214
Stahl S, Markowitz JS, Gutterman EM, Papadopoulos G.
Co-use of Donepezil and Hypnotics Among Alzheimer’s Disease Patients Living In the Community.
Journal of Clinical Psychiatry 2003; 64: 466-472
Markowitz JS, Gutterman EM, Lilieneld S, Papadopoulos G.
Sleep-Related Outcomes in Persons with Mild to Moderate Alzheimer's Disease in a Placebo-Controlled Trial of Galantamine.
Sleep 2006; 26(5): 602-606
2002
Caro JJ, Ward A, Ishak K, Migliaccio-Walle K, Getsios D,Papadopoulos G, Torfs K.
To What Degree Does Cognitive Impairment in Alzheimer’s Disease Predict Dependence of Patients on Caregivers.
BMC Neurology 2002; 2:6
Small GW, McDonnell DD, Brooks RL. Papadopoulos G.
The impact of symptom severity on the cost of Alzheimer’s disease.
J Am Geriatr Soc 2002; 50: 321-327
2001
Neumann PJ, Araki SS, Arcelus A, Longo A, , Kosik KS, Bhattacharjya A Papadopoulos G.
Transition Probabilities in Alzheimer’s Disease: Estimates of Disease Progression and Institutionalization by Age, Gender, and Behavioral Symptoms.
Neurology 2001; 57: 957-964
1990
Exner T., Papadopoulos G., Sahman N. & Koutts J.
Solvent extraction of test plasma for improved recovery of lupus anticoagulant activity.
Thomb Haemostas 1990; 64(1): 121-123
Exner T., Papadopoulos G. & Koutts J.
Use of a simplified dilute Russell's Viper venom time (DRVVT) confirms heterogeneity among "lupus anticoagulants".
Blood Coag Fibrinolys 1990; 1: 259-266; 1990